Friday, December 05, 2025 | 01:45 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

Image
premium

Prosenjit Datta
By now, it is abundantly clear that the world will need to live with coronavirus for some more time despite several vaccines being available. The virus mutations will require more and better vaccines to be developed.

Last year, it had briefly looked as if different players and countries had put aside their individual interests to find a solution for the pandemic jointly. There was unprecedented cooperation between multinational drug firms, research labs, biotech start-ups and governments, to develop cures for the virus. By the end of 2020 though, vaccine nationalism, vaccine politics and profiteering had reared their heads.

Developed countries stockpiled vaccine
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper